CD8A and neoplasm: In the study by Russo et al., 2024, DAC combined with PeptiCRAd not only suppressed tumor growth but also induced a spatial reorganization of intratumoral CD8+ T cells and reduced immune exhaustion phenotypes (PD-1+TIM-3+), signaling improved T cell functionality [59].